Medium vs Low Oxygen Threshold for the Surfactant Administration

Status Not yet recruiting

Clinical Trial Summary

The aim of this study will be to assess the better fraction inspired oxygen (FiO2) threshold for the surfactant treatment in preterm infants with respiratory distress syndrome (RDS) randomized to receive exogenous surfactant at 25% or 35% of FiO2 threshold. The pulmonary gas-exchanges will be evaluated by oxygen saturation (SpO2) to FiO2 ratio (SFR) and will be used to define the better FiO2 threshold for the surfactant treatment.

Clinical Trial Description

Exogenous surfactant therapy is an effective treatment of neonatal respiratory distress syndrome (RDS) and has been associated with reduced severity of respiratory distress and mortality. The 2019 European guidelines for neonatal RDS treatment suggest as the threshold of inspired oxygen (FiO2) for the surfactant treatment at 30% for all gestational age, but there are no randomized studies that confirm this indication. Some observational studies reported that a relevant number of patients who are not routinely treated with surfactant had respiratory complications, thus they received exogenous surfactant. To date, the optimal FiO2 threshold for surfactant administration remains unclear. In this single-center, randomized, phase 4 trial, preterm infants (gestational age<32 weeks) with RDS will be randomized to receive exogenous surfactant at 25% or 35% of FiO2 threshold. According to the unit policy, the exogenous surfactant will be administered by an endotracheal tube in intubated infants, or by Intubation-Surfactant-Extubation (InSurE) / Less Invasive Surfactant Administration (LISA) methods in infants who will not remain intubated. The method used for the surfactant administration will be at the discretion of the caring physician. ;

Study Design

Related Conditions & MeSH terms

Respiratory Distress Syndrome
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Syndrome

Clinical Trial Details

NCT number	NCT04199364
Study type	Interventional
Source	Ospedali Riuniti Ancona
Contact	Virgilio Carnielli, MD, PHD
Phone	0715962045
Email	v.carnielli@staff.univpm.it
Status	Not yet recruiting
Phase	Phase 4
Start date	June 1, 2021
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06168149` - The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
Recruiting	`NCT03670732` - CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure	N/A
Recruiting	`NCT02901652` - NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome	N/A
Completed	`NCT02249143` - Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants	N/A
Suspended	`NCT01852916` - NHFOV Versus NCPAP to Prevent Exubation Failure	N/A
Completed	`NCT00208039` - Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates	N/A
Recruiting	`NCT03510169` - Use of Gentle Synchronized Negative Pressure in Helping Babies Breathe	N/A
Completed	`NCT00004494` - Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis	Phase 1
Completed	`NCT00006058` - Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns	N/A
Completed	`NCT00004805` - Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death	N/A
Completed	`NCT03292562` - A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation	N/A
Completed	`NCT05948332` - Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation
Completed	`NCT05038514` - The Effect of Music Therapy in COVID-19 Patients Given Prone Position	N/A
Active, not recruiting	`NCT04079829` - Postoperative Respiratory Abnormalities
Completed	`NCT05462509` - Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda	N/A
Active, not recruiting	`NCT03808402` - The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS
Completed	`NCT01812681` - Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities	N/A
Not yet recruiting	`NCT01440868` - Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome	N/A
Completed	`NCT01517958` - Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates	N/A
Completed	`NCT01222247` - Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.